Optimizing Outcomes in Relapsed and Refractory Multiple Myeloma: Personalized Approaches and Adverse Event Management

Professor Eirini Katodritou has financial relationships or affiliations through receiving honoraria from Amgen, GSK, and Janssen, and research funding from Abbvie, GSK, Janssen, Karyopharm, and Pfizer. Professor Shaji Kumar has extensive financial relationships or affiliations, including consulting for numerous companies such as AbbVie, Amgen, ArcellX, Beigene, BMS, Carsgen, Epizyme, Glycostem, GSK, Janssen, K36, Menarini, Moderna, Pfizer, Regeneron, Roche-Genentech, Sanofi, Takeda, Telogenomics, Trillium, and Window Therapeutics, with personal payments also from Antengene, Calyx, CVS Caremark, and BD Biosciences. Additionally, he has received clinical trial support from AbbVie, Amgen, Astra Zeneca, BMS, Carsgen, GSK, Gracell Bio, Janssen, Oricell, Roche-Genentech, Sanofi, Takeda, and Telogenomics. In contrast, Professor Evangelos Terpos has had no financial interests, relationships, or affiliations in the past 24 months. Meanwhile, Professor Suzanne Lentzsch has financial relationships or affiliations through serving on advisory boards for Astra Zeneca, BMS, GSK, Janssen, Karyopharm, Regeneron, Sanofi, and Pfizer, as well as being a speaker for GSK and Regeneron, and a DMSB member for BMS and Janssen. The authors have nothing to report.